Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | METAP2 | P50579 | 8/20 | 0.38 |
| ▸ | METAP1 | P53582 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30910814 | 1.00 | BIRC2 (0.43) | BIRC2DPP4DPP8DPP9CA14 | |
| SCHEMBL30910783 | 1.00 | BIRC2 (0.43) | BIRC2DPP4DPP8DPP9CA14 | |
| SCHEMBL30910809 | 1.00 | BIRC2 (0.43) | BIRC2DPP4DPP8DPP9CA14 | |
| Hydrochloric Acid SCHEMBL30910737 | 0.98 | BIRC2 (0.42) | BIRC2DPP4DPP8DPP9CA14 | |
| SCHEMBL27524339 | 0.87 | BIRC2 (0.42) | BIRC2DPP4DPP8DPP9CA14 | |
| SCHEMBL10700935 | 0.87 | BIRC2 (0.42) | BIRC2DPP4DPP8DPP9CA14 | |
| SCHEMBL10748731 | 0.87 | BIRC2 (0.42) | BIRC2DPP4DPP8DPP9CA14 | |
| Hydrochloric Acid SCHEMBL23404051 | 0.86 | BIRC2 (0.41) | BIRC2DPP4DPP8DPP9CA14 | |
| SCHEMBL4889893 | 0.85 | SLC7A5 (0.45) | BIRC2CA14TSHRMEN1KMT2A | |
| SCHEMBL27349073 | 0.85 | SLC7A5 (0.45) | BIRC2CA14TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398966-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-12-05 | — | — | US | disclosed |
| US-11998610-B2 | Conjugates and methods of using the same | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11998610-B2 | Conjugates and methods of using the same | CD47, CD44, CD74 | BIRC2 1554/4885DPP4 1285/4885DPP8 693/4885 |
| US-20240398966-A1 | CONJUGATES AND METHODS OF USING THE SAME | CD47, CD44, CD74 | BIRC2 1554/4885DPP4 1285/4885DPP8 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.